We are live on ! Find out more
BIVV

Bioverativ Inc. Common Stock
BIVV

Delisted

BIVV was delisted on the 8th of March, 2018.

2 hedge funds and large institutions have $27K invested in Bioverativ Inc. Common Stock in 2018 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 449 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 4592 (-457)

100% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 449

100% less funds holding in top 10

Funds holding in top 10: 50 (-5)

100% less capital invested

Capital invested by funds: $5.76B → $27K (-$5.76B)

Holders
2
Holders Change
-457
Holders Change %
-99.56%
% of All Funds
0.05%
Holding in Top 10
Holding in Top 10 Change
-5
Holding in Top 10 Change %
-100%
% of All Funds
New
1
Increased
Reduced
Closed
449
Calls
Puts
Net Calls
Net Calls Change

BIVV Hedge Fund Activity: Q1 2018 in Review

2 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Bioverativ Inc. Common Stock (BIVV) for Q1 2018, worth a combined $27K — down 100% from $5.76B a quarter earlier.

Sellers outnumbered buyers: 449 funds closed out of BIVV and 1 opened new positions — a net loss of 448 holders — while 0 trimmed existing stakes and 0 added.

The largest buyer was Archford Capital Strategies, opening a new position worth an estimated $2.28K. The largest seller was BlackRock, exiting entirely with an estimated $585M sold.

  • 2 institutional investors held Bioverativ Inc. Common Stock (BIVV) as of Q1 2018, down from 459 in Q4 2017.
  • Funds reported $27K of Bioverativ Inc. Common Stock stock for Q1 2018, down 100% quarter-over-quarter.
  • 1 fund opened new Bioverativ Inc. Common Stock positions in Q1 2018 and 449 closed out, a net change of -448 holders.
  • The largest Bioverativ Inc. Common Stock buyer in Q1 2018 was Archford Capital Strategies, an estimated $2.28K added.
  • The largest Bioverativ Inc. Common Stock seller in Q1 2018 was BlackRock, an estimated $585M sold.

Based on aggregated 13F filings for Q1 2018.